Designing a Delinked Incentive for Critical Antibiotics: Lessons from Norway

Årdal, Christine; Johnsen, Jostein; Johansen, Karianne

doi:10.1177/1073110518782914

Cited by 3 publications

(1 citation statement)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, any efforts to implement the model would add valuable operational knowledge. Årdal et al 11 share the experience of a cross-section of Norwegian health agencies designing a delinked antibiotic incentive suitable for national context, including the Norwe-gian legal framework, market size, health system, and AMR situation. Their conclusion is that in Norway a partially delinked model fulfills the aims with the least disruptive impact.…”

Section: Pull Incentives: How Would Successful Antibiotic Innovation mentioning

confidence: 99%

Stimulating Research and Development of New Antibiotics While Ensuring Sustainable Use and Access: Further Insights from the DRIVE-AB Project and Others

Bettiol¹,

Hackett²,

Harbarth³

2018

J. Law. Med. Ethics

View full text Add to dashboard Cite

Global discussions are ongoing on how to stimulate antibiotic research and development in order to provide patients with new antibiotics able to address the challenges of antimicrobial resistance. In this supplement, we present nine articles derived from the research performed as part of the Innovative Medicine Initiative-funded DRIVE-AB project and others. These publications provide new evidence and arguments in the debate around economic incentives to stimulate antibiotic innovation, including characteristics, implementation and governance.

show abstract

Section: Pull Incentives: How Would Successful Antibiotic Innovation mentioning

confidence: 99%

Stimulating Research and Development of New Antibiotics While Ensuring Sustainable Use and Access: Further Insights from the DRIVE-AB Project and Others

Bettiol¹,

Hackett²,

Harbarth³

2018

J. Law. Med. Ethics

View full text Add to dashboard Cite

show abstract

Drug pricing models, no ‘one-size-fits-all’ approach: a systematic review and critical evaluation of pricing models in an evolving pharmaceutical landscape

Manders,

van den Berg,

de Visser

et al. 2024

Eur J Health Econ

View full text Add to dashboard Cite

Access to new medicines is crucial for patients but increasingly sparks discussion due to high prices. Simultaneously, the growing emphasis on specialized products and uncertainty surrounding the long-term effectiveness of new drug classes brought to the market underscore the need for innovative pricing approaches. A systematic literature review of pharmaceutical pricing models, accompanied by a critical appraisal, was conducted to offer insights contributing to novel approaches balancing sustainable pharmaceutical innovation with affordability and accessibility for patients. Six different pricing models are identified: value based pricing, basic cost-based pricing, and four more comprehensive pricing models incorporating numerous elements: the cancer-drug-pricing model, AIM model, (Nuijtens) discounted cash flow, and the real-option rate of return method. Although there are many similarities among the models, each has unique assumptions for implementation. For instance, all models except for the standard incremental cost-effectiveness ratio and basic cost-based pricing consider the number of eligible patients and the remaining patent period. Only the AIM model and the Nuijtens discounted cash flow model use lump sums. Both the latter and the real-option rate of return method explicitly include the cost of capital as a major cost-based component. Recognizing the diverse applications of each model highlights the need for more differential and dynamic pricing tailored to the characteristics and therapeutic areas of each drug. Additionally, the study underscores the importance of cost transparency in achieving this goal. Consequently, these findings can help stakeholders develop sustainable and affordable drug pricing mechanisms that address the complexities of the ever-changing pharmaceutical landscape.

show abstract

Encouraging the Development of New Antibiotics: Are Financial Incentives the Right Way Forward? A Systematic Review and Case Study

Dutescu¹,

Hillier²

2021

IDR

109

View full text Add to dashboard Cite

Antibiotic resistance is an urgent public health threat that has received substantial attention from the world’s leading health agencies and national governmental bodies alike. However, despite increasing rates of antibiotic resistance, pharmaceutical companies are reluctant to develop new antibiotics due to scientific, regulatory, and financial barriers. Nonetheless, only a handful of countries have addressed this by implementing or proposing financial incentive models to promote antibiotic innovation. This study is comprised of a systematic review that aimed to understand which antibiotic incentive strategies are most recommended within the literature and subsequently analyzed these incentives to determine which are most likely to sustainably revitalize the antibiotic pipeline. Through a case study of Canada, we apply our incentive analysis to the Canadian landscape to provide decision-makers with a possible path forward. Based on our findings, we propose that Canada support the ongoing efforts of other countries by implementing a fully delinked subscription-based market entry reward. This paper seeks to spark action in Canada by shifting the national paradigm to one where antibiotic research and development is prioritized as a key element to addressing antibiotic resistance.

show abstract

Designing a Delinked Incentive for Critical Antibiotics: Lessons from Norway

Cited by 3 publications

References 9 publications

Stimulating Research and Development of New Antibiotics While Ensuring Sustainable Use and Access: Further Insights from the DRIVE-AB Project and Others

Stimulating Research and Development of New Antibiotics While Ensuring Sustainable Use and Access: Further Insights from the DRIVE-AB Project and Others

Drug pricing models, no ‘one-size-fits-all’ approach: a systematic review and critical evaluation of pricing models in an evolving pharmaceutical landscape

Encouraging the Development of New Antibiotics: Are Financial Incentives the Right Way Forward? A Systematic Review and Case Study

Contact Info

Product

Resources

About